News center_News center_Kintor Pharmaceutical Limited

Kintor Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine

 发布时间 : 2023-10--28  点击量 : 0

Suzhou, October 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the results of the Phase Ib/II clinical trial of ALK-1 antibody GT90001 combined with PD-1 antibody nivolumab in the treatment of advanced hepatocellular carcinoma (HCC) were published online by the well-known journal BMC Medicine (Impact factor: 11.806). The results showed that this combination regimen is well-tolerated and has promising anti-tumor activity in patients with recurrent advanced HCC, with a confirmed overall response rate (ORR) of 30% and a remarkable long-tail effect.

Kintor Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

 发布时间 : 2023-10--11  点击量 : 0

Suzhou, October 11, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration (NMPA) for treatment of idiopathic pulmonary fibrosis (IPF).

Kintor Pharma Announces 2023 Interim Results and Recent Business Highlights

 发布时间 : 2023-08--28  点击量 : 0

Suzhou, August 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma” or “the company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2023 interim results and released an update on its recent business highlights.

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

 发布时间 : 2023-08--22  点击量 : 0

Suzhou, August 22, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera (PROTAC) compound GT20029 in China for the treatment of male androgenetic alopecia (AGA). GT20029 was developed based on the in-house PROTAC platform and is the world’s first topical PROTAC compound which has entered the Phase II clinical stage.

Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA

 发布时间 : 2023-07--19  点击量 : 0

Suzhou, July 19, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023.

Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

 发布时间 : 2023-05--11  点击量 : 0

Suzhou, May 11, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia (“AGA”) in the US has been completed successfully. The results are statistically and clinically meaningful, and demonstrated a favorable safety profile. The company is preparing for subsequent FDA meetings on the results of the Phase II clinical trial, and intends to commence Phase III clinical trial in the US/globally.